Real‐world utility of early measurable residual disease assessments by multi‐parametric flow cytometry in adult patients with B‐lymphoblastic leukemia receiving <scp>Hyper‐CVAD</scp> induction chemotherapy-Reference-Cited by-同舟云学术

Real‐world utility of early measurable residual disease assessments by multi‐parametric flow cytometry in adult patients with B‐lymphoblastic leukemia receiving Hyper‐CVAD induction chemotherapy

Published:2022-11-11 Issue:2 Volume:110 Page:168-176
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:European J of Haematology

Author:

Nedumannil Rithin¹²³^ORCID,Ritchie David³⁴,Bajel Ashish³⁴,Ng Ashley P.³⁵,Harrison Simon J.³⁴,Westerman David¹³⁴

Affiliation:

1. Department of Pathology Peter MacCallum Cancer Centre Melbourne Victoria Australia

2. Department of Diagnostic Haematology Royal Melbourne Hospital Parkville Victoria Australia

3. Department of Clinical Haematology Peter MacCallum Cancer Centre and The Royal Melbourne Hospital Melbourne Victoria Australia

4. Sir Peter MacCallum Department of Oncology The University of Melbourne Parkville Victoria Australia

5. Immunology Division Walter and Eliza Hall Institute of Medical Research Parkville Australia

Publisher

Wiley

Subject

Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ejh.13890

Reference25 articles.

1. Modern Therapy of Acute Lymphoblastic Leukemia

2. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation

3. Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia

4. Has MRD monitoring superseded other prognostic factors in adult ALL?

5. Treatment of High-Risk Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia in Adolescents and Adults According to Early Cytologic Response and Minimal Residual Disease After Consolidation Assessed by Flow Cytometry: Final Results of the PETHEMA ALL-AR-03 Trial